• The Ride for Roswell: Rolling Around The Track August 7
    Impact Journals is participating with Team Open Access in the annual cycling event to end cancer: The Ride for Roswell. This fundraiser is hosted by Roswell Park Comprehensive Cancer Center in Buffalo, New York.
  • Behind the Study: ONC201, TRAIL, and Breast Cancer
    Founding Oncotarget Editorial Board Member, Dr. Wafik S. El-Deiry, and recent MD/PhD graduate of Temple University, Dr. Marie D. Ralff, discuss their 2020 study published by Oncotarget entitled, “TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic.”
  • Behind the Study: PRAME Associated with Increased Metastatic Risk
    Dr. Matthew G. Field discusses this 2016 high-performing study published by Oncotarget entitled, “Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.”

View All Posts >>


Read about community news and events sponsored by Oncotarget – a bi-weekly peer-reviewed open access scientific journal focusing on all topics surrounding cancer research. Visit Oncotarget.org for the latest articles about new and trending peer-reviewed scientific papers published by Oncotarget, part of the Impact Journals family of scientific publications.


Oncotarget is published by Impact Journals of Orchard Park, New York. Impact Journals meets the standards established Wellcome Trust Publisher Requirements and is included on the Wellcome Trust List of Compliant Publishers.

Oncotarget is proud to have multiple Nobel Prize winning members on its editorial board, in addition to editors who have won the Lasker Prize and other prestigious recognitions. The open-access model employed by Oncotarget allows for free dissemination of thoroughly vetted peer-reviewed research material to the general public, leading to bigger and more frequent scientific breakthroughs. Because of Oncotarget’s uniquely varied scope, the journal has consistently published research on a wide range of subject areas, allowing readers to access an unparalleled diversity of knowledge in only one publication.

The founding editors of Oncotarget are Mikhail (Misha) Blagosklonny and Andrei Gudkov. Dr. Blagosklonny is well-known for his research in the field of aging, having published numerous papers on the subject. Mikhail is credited for advancing groundbreaking research of the drug Rapamycin, an anti-aging medicine that has shown to slow down the aging process. Having been featured in numerous publications on aging including a Scientific American article titled “A New Path to Longevity,” Mikhail continues to provide meaningfully important contributions to the scientific community.


Dr. Blagosklonny can be followed on Twitter @Blagosklonny and you can visit his website here.

To get in touch with Oncotarget, please visit our website. The journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.

2021 Ride for Roswell